- Home
- MOBX vs OCX Comparison
MOBX vs OCX Comparison
Compare MOBX & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- OCX
- Stock Information
- Founded
- MOBX 2020
- OCX 2009
- Country
- MOBX United States
- OCX United States
- Employees
- MOBX N/A
- OCX N/A
- Industry
- MOBX
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MOBX
- OCX Health Care
- Exchange
- MOBX Nasdaq
- OCX Nasdaq
- Market Cap
- MOBX 29.9M
- OCX 35.1M
- IPO Year
- MOBX N/A
- OCX N/A
- Fundamental
- Price
- MOBX $1.66
- OCX $1.96
- Analyst Decision
- MOBX
- OCX Buy
- Analyst Count
- MOBX 0
- OCX 3
- Target Price
- MOBX N/A
- OCX $4.42
- AVG Volume (30 Days)
- MOBX 939.6K
- OCX 71.5K
- Earning Date
- MOBX 02-18-2025
- OCX 11-12-2024
- Dividend Yield
- MOBX N/A
- OCX N/A
- EPS Growth
- MOBX N/A
- OCX N/A
- EPS
- MOBX N/A
- OCX N/A
- Revenue
- MOBX $6,442,000.00
- OCX $709,000.00
- Revenue This Year
- MOBX N/A
- OCX N/A
- Revenue Next Year
- MOBX N/A
- OCX $106.34
- P/E Ratio
- MOBX N/A
- OCX N/A
- Revenue Growth
- MOBX 426.31
- OCX N/A
- 52 Week Low
- MOBX $0.55
- OCX $1.92
- 52 Week High
- MOBX $3.62
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- MOBX 57.51
- OCX 33.88
- Support Level
- MOBX $1.13
- OCX $2.05
- Resistance Level
- MOBX $1.34
- OCX $2.18
- Average True Range (ATR)
- MOBX 0.21
- OCX 0.17
- MACD
- MOBX -0.03
- OCX -0.01
- Stochastic Oscillator
- MOBX 80.28
- OCX 5.60
About MOBX Mobix Labs Inc.
Mobix Labs Inc is a fabless semiconductor company developing disruptive next generation wireless and connected solutions that are designed to cater to a broad range of applications in markets including 5G infrastructure, satellite communications, automotive, consumer electronics, e-mobility, healthcare, infrastructure and defense.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.